Novel mechanisms involving chemically modified tetracycline 3 cytotoxicity.

Abstract:

:Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including increased intracellular autophagy level and high-mobility group box 1 (HMGB1)release were involved. In addition, a major Danshen ingredient, tanshinone IIA sodium sulfonate (TSN-SS),significantly increased the cytotoxic effects of CMT-3 in HepG2 cells. Combining CMT-3 with TSN-SS led to enhanced accumulation of endogenous LC3-II, but reduced HMGB1 cytoplasmic translocation. Altogether, these findings suggest that autophagy and HMGB1 release may play important roles in the anticancer effect of CMT-3. As an ovel candidate for cancer therapy, CMT-3 may be used in combination with TSN-SS, which possibly facilitates the execution of a death signal (e.g. autophagy) and prevents the survival of an inducer (e.g. HMGB1 cytoplasmic translocation), thus improving its therapeutic effect.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Zhao L,Xu J,Jiao Y,Wang H,Fan S

doi

10.1097/cad.0000000000000144

subject

Has Abstract

pub_date

2014-11-01 00:00:00

pages

1165-74

issue

10

eissn

0959-4973

issn

1473-5741

journal_volume

25

pub_type

杂志文章
  • Potential antineoplastic activity of keto-C-glycosides--a new family of cytostatic agents.

    abstract::We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199208000-00006

    authors: Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

    更新日期:1992-08-01 00:00:00

  • Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.

    abstract::High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer has been associated with a poor prognosis, indicating that VEGF could be linked to the efficacy of chemotherapy and radiotherapy. It has also been suggested that radiation resistance is partly due to tumour cell production of a...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834ea5b3

    authors: Heravi M,Tomic N,Liang L,Devic S,Holmes J,Deblois F,Radzioch D,Muanza T

    更新日期:2012-06-01 00:00:00

  • D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.

    abstract::Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 an...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-200102000-00010

    authors: Duffaud F,van der Burg ME,Namer M,Vergote I,Willemse PHB,ten Bokkel Huinink W,Guastalla JP,Nooij,Kerbrat P,Piccart M,Tumolo S,Favalli G,van der Vange N,Lacave AJ,Wils J,Splinter TA,Einhorn N,Roozendaal KJ,Rosso R,Ve

    更新日期:2001-02-01 00:00:00

  • Tamoxifen as a potential treatment of glioma.

    abstract::Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199808000-00001

    authors: Mastronardi L,Puzzilli F,Ruggeri A

    更新日期:1998-08-01 00:00:00

  • Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells.

    abstract::Previous in vitro biochemical studies have revealed that the antitumor drug leinamycin causes oxidative DNA damage and DNA alkylation. However, it is still not clear whether the same mechanism(s) of action operate in cultured human tumor cells. Here, we evaluated the effects of leinamycin in the human pancreatic carci...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000136886.72917.6f

    authors: Bassett S,Urrabaz R,Sun D

    更新日期:2004-08-01 00:00:00

  • Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy.

    abstract::The two major steps in our study on the treatment of skin carcinomas by photochemotherapy (PCT) were the development of a skin tumor model in Hairless mice by a chemical carcinogenesis and the use of fluorescence spectroscopy, a semi-quantitative and non-invasive method, in order to determine the time after i.p. injec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200002000-00004

    authors: Bossu E,Padilla-Ybarra JJ,Notter D,Vigneron C,Guillemin F

    更新日期:2000-02-01 00:00:00

  • Docetaxel in squamous cell cancer of the head and neck.

    abstract::Single-agent docetaxel induces a response in 21-42% of patients with recurrent squamous cell cancer of the head and neck (SCCHN). When used in combination with 5-fluorouracil (5-FU), response rates (RRs) of between 24 and 27% have been reported. In contrast, in combination with cisplatin, docetaxel has achieved a RR o...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Posner MR

    更新日期:2001-02-01 00:00:00

  • Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds.

    abstract::Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200606000-00007

    authors: Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

    更新日期:2006-06-01 00:00:00

  • Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?

    abstract::Intensive cisplatin and oral etoposide for relapsed epithelial ovarian cancer (EOC), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all patients with relapsed EOC treated on the VDB protocol at the Cambridge Gynae-Oncology Cent...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000320

    authors: Gounaris I,Iddawela M,Parkinson C,Pratt J,Hatcher H,Basu B,Tan LT,Brenton JD,Earl HM

    更新日期:2016-03-01 00:00:00

  • Combretastatin A4 phosphate.

    abstract::Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200403000-00001

    authors: West CM,Price P

    更新日期:2004-03-01 00:00:00

  • New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

    abstract::An international meeting on 'New Drugs in Cancer Therapy' was held at the National Tumor Institute of Naples, on 17-18 June 2004. The first session of the meeting focused on analogs of conventional anti-cancer drugs, such as taxanes, platinum compounds, anthracyclines and topoisomerase I inhibitors. The data of a phas...

    journal_title:Anti-cancer drugs

    pub_type:

    doi:10.1097/00001813-200502000-00014

    authors: Caponigro F,Basile M,de Rosa V,Normanno N

    更新日期:2005-02-01 00:00:00

  • Generation and characterization of a paclitaxel-resistant human gastric carcinoma cell line.

    abstract::The main aim of this study was to establish a novel paclitaxel (PTX)-resistant human gastric carcinoma cell line and to investigate its biological significance. A cell line, MGC803/PTX, was established by gradually increasing PTX density on the basis of MGC803 over a period of 10 months. In addition, a pair of resista...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000601

    authors: Fu L,Yin F,Li XR,Han BK,Zhang C,Wang JW,Wang YQ,Bi YF,Liu HM

    更新日期:2018-07-01 00:00:00

  • Tumour flare reaction in cancer treatments: a comprehensive literature review.

    abstract::In the past decade, tumour flare reaction (TFR) was considered as a new side effect associated with immunomodulatory agents (IMiDs) and as a condition of chronic lymphocytic leukaemia (CLL). However, this phenomenon is also observed with immune checkpoint inhibitors in solid tumours. It is still poorly understood and ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000814

    authors: Taleb B A

    更新日期:2019-10-01 00:00:00

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice.

    abstract::The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against carcinomatous peritonitis in mice. In the first experiment using carcinomatous peritonitis caused by i.p. inoculation of 10(6) M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body weight into two grou...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199506000-00012

    authors: Tsujimoto H,Hagiwara A,Osaki K,Ohyama T,Sakakibara T,Sakuyama A,Ohgaki M,Imanishi T,Watanabe N,Yamazaki J

    更新日期:1995-06-01 00:00:00

  • Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.

    abstract::Glioma is a primary intracranial malignant tumor with poor prognosis. In this study, we aimed to develop transferrin (Tf)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles to deliver temozolomide (TMZ) to glioma and evaluate their efficacy to kill glioma. TMZ-loaded nanoparticles were prepared by nanoprecipi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000754

    authors: Mao J,Meng X,Zhao C,Yang Y,Liu G

    更新日期:2019-07-01 00:00:00

  • A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.

    abstract::The aim of this study was to investigate in a randomized trial the activity of perioperative chemotherapy in patients treated with preoperative chemotherapy for locally advanced breast cancer and to compare it with the preoperative chemotherapy alone. Patients with cT2-3 N0-2 M0 histologically proven breast cancer, wi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.cad.0000236306.43209.2b

    authors: Rocca A,Peruzzotti G,Ghisini R,Viale G,Veronesi P,Luini A,Intra M,Pietri E,Curigliano G,Giovanardi F,Maisonneuve P,Goldhirsch A,Colleoni M

    更新日期:2006-11-01 00:00:00

  • Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.

    abstract::Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199710000-00004

    authors: Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

    更新日期:1997-10-01 00:00:00

  • A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections.

    abstract::Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clinical trials. The aims of this single-center, open label, phase I clinical trial were to investigate the safety and tolerability of CA4P admin...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000070

    authors: Liu P,Qin Y,Wu L,Yang S,Li N,Wang H,Xu H,Sun K,Zhang S,Han X,Sun Y,Shi Y

    更新日期:2014-04-01 00:00:00

  • Baicalin induces apoptosis in SW480 cells through downregulation of the SP1 transcription factor.

    abstract::Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000708

    authors: Ma W,Liu X,Du W

    更新日期:2019-02-01 00:00:00

  • Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

    abstract::Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00001813-199810000-00003

    authors: Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

    更新日期:1998-10-01 00:00:00

  • Alpha-tocopherol ameliorates cyclophosphamide-induced hyperlipidemia in fibrosarcoma-bearing rats.

    abstract::Cyclophosphamide, an alkylating agent, is currently being used for the treatment of various types of cancer, either alone or in combination with other cytostatic drugs. However, cyclophosphamide has a detrimental effect on lipid metabolism and causes hyperlipidemia in patients. Since alpha-tocopherol is known to reduc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199512000-00009

    authors: Ilanchezhian S,Thangaraju M,Sasirekha S,Sachdanandam P

    更新日期:1995-12-01 00:00:00

  • In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.

    abstract::Previous investigations have indicated the possibility to circumvent multidrug resistance (MDR) by incorporation of an anthracycline into liposomes. We examined the in vitro cytotoxicity and cellular drug accumulation of the anthracyclines daunorubicin and doxorubicin compared with the commercially available liposomal...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199911000-00008

    authors: Wang Y,Eksborg S,Lewensohn R,Lindberg A,Liliemark E

    更新日期:1999-11-01 00:00:00

  • Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer.

    abstract::This study aims to explore the effect and mechanism of pyruvate kinase M2 (PKM2) on chemotherapy resistance of estrogen receptor-positive breast cancer (ER BC) by regulating aerobic glycolysis. The expression of PKM2 in ER BC MCF-7 cells, T47D cells and MCF-7/ADR cells (which are subject to adriamycin/ADR induction) w...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000624

    authors: Qian Y,Bi L,Yang Y,Wang D

    更新日期:2018-08-01 00:00:00

  • Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells.

    abstract::The anticancer effects of artesunate (ART) have been well documented. However, its potential against skin cancer has not been explored yet. Herein we reported that 60 μmol/l ART effectively inhibited A431 (human epidermoid carcinoma cells) growth but not that of HaCaT (normal human keratinocyte cells). Our results rev...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328350e8ac

    authors: Jiang Z,Chai J,Chuang HH,Li S,Wang T,Cheng Y,Chen W,Zhou D

    更新日期:2012-07-01 00:00:00

  • Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells.

    abstract::Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283634dd0

    authors: Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

    更新日期:2013-09-01 00:00:00

  • Repeat dose study of the novel proapoptotic chemotherapeutic agent alpha-tocopheryloxy acetic acid in mice.

    abstract::Alpha-tocopheryloxy acetic acid (α-TEA) is an ether derivative of vitamin E and has been shown to suppress tumor growth in various murine and human xenograft tumor models, including melanoma, breast, lung, prostate, and ovarian cancers. The purpose of this study was to assess its safety and pharmacokinetics after repe...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834f6271

    authors: Hahn T,Akporiaye ET

    更新日期:2012-04-01 00:00:00

  • Ampelopsin sodium exhibits antitumor effects against bladder carcinoma in orthotopic xenograft models.

    abstract::The aim of this study was to establish xenograft models of tumor in mice bladder and evaluate the antitumor efficacy of ampelopsin sodium (Amp-Na). A total of 2×10 human bladder carcinoma EJ cells and murine sarcoma 180 cells were instilled into the bladder of BALB/c nu/nu mice and Swiss mice after preconditioning to ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835019f9

    authors: Zhang B,Dong S,Cen X,Wang X,Liu X,Zhang H,Zhao X,Wu Y

    更新日期:2012-07-01 00:00:00

  • Cytotoxic effects and pharmacokinetic analysis of combined adriamycin and X-ray treatments in human organotypic cell cultures.

    abstract::Organotypic cultures of human A549 cells were used as a tumor model to investigate sequence effects for combination treatments with adriamycin (ADR) and X-irradiation. Initial drug exposure led to the greatest cytotoxic effect especially when X-rays were delivered 24 h later and this subsequent irradiation did not sig...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199204000-00010

    authors: Chevillard S,Vielh P,Campana F,Bastian G,Coppey J

    更新日期:1992-04-01 00:00:00

  • A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.

    abstract::9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199801000-00004

    authors: Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

    更新日期:1998-01-01 00:00:00

  • Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells.

    abstract::This study was performed to evaluate the role of protein kinase C (PKC) activity in the development of chemoresistance in clinical breast cancer cells. To simulate the clinical situation, native tumor cells derived from 10 patients with advanced breast cancer were brought into short-term cultures, and treated with ant...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200403000-00011

    authors: Schöndorf T,Hoopmann M,Breidenbach M,Rein DT,Göhring UJ,Becker M,Mallmann P,Kurbacher CM

    更新日期:2004-03-01 00:00:00